Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

NCT03916419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Stage IIB Non-Small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IIIC Non-Small Cell Lung Cancer

Interventions

DEVICE: ViewRay MR-Linear Accelerator
RADIATION: Radiation therapy
DRUG: Paclitaxel
DRUG: Carboplatin AUC
BIOLOGICAL: Durvalumab

Sponsor

Washington University School of Medicine